To print: Select File and then Print from your browser's menu

Title: Health Canada Endorsed Important Safety Information on Rapamune (Sirolimus)

"Health Canada Endorsed Important Safety Information on Rapamune (Sirolimus)"

MARKHAM, CANADA -- August 25, 2006 -- Wyeth Pharmaceuticals, Division of Wyeth Canada, in consultation with Health Canada, wishes to provide Canadian kidney transplant patients with new safety information regarding an increased risk of rejection in new kidney transplant recipients receiving a combination of anti-rejection drugs. Specifically this involves Rapamune® (sirolimus), mycophenolate mofetil, and corticosteroids, used in combination with interleukin-2 receptor antibody induction. This information was discovered in the course of two clinical studies conducted to determine if this combination therapy would provide better kidney function after transplantation. The results of these two clinical studies have shown a higher rate of acute rejection in kidney transplant patients who received the investigational combination of drugs compared to patients receiving the usual standard therapy, which includes cyclosporine or tacrolimus, following kidney transplantation. It is important to note that these results apply only to the specific combination of drugs studied in these clinical trials. In Canada, Rapamune® is authorized for the prevention of rejection only in patients who have received kidney transplants, and must be used in combination with other anti-rejection drugs (such as cyclosporine or tacrolimus) in the period immediately following transplantation. Such patients should continue to use Rapamune® as prescribed. Patients taking Rapamune® should not discontinue or change their medication without discussion with their transplant physician. Wyeth has sent a letter to transplant physicians informing them of this new safety information. A copy of the Healthcare professional letter and this communication are available on the Health Canada website (http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2006/index_e.html). Wyeth continues to work closely with Health Canada to monitor adverse reactions and to ensure that up-to-date information regarding the use of Rapamune® is available. Managing marketed health product-related adverse reactions depends on health-care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of or other serious or unexpected adverse reactions in patients receiving Rapamune® should be reported to Wyeth Canada, or Health Canada at the following addresses: Wyeth Canada Medical Information and Pharmacovigilance 50 Minthorn Blvd. Markham, Ontario L3T 7Y2 Tel: 1 -800-461-8844 Fax: (905) 470-4385 Any suspected adverse reaction can also be reported to: Canadian Adverse Drug Reaction Monitoring Program (CADRMP) Marketed Health Products Directorate HEALTH CANADA Address Locator: 0701C OTTAWA, Ontario, K1A 0K9 Tel: (613) 957-0337 or Fax: (613) 957-0335 To report an Adverse Reaction, consumers and health professionals may call toll free: Tel: 866 234-2345 Fax: 866 678-6789 cadrmp@hc-sc.gc.ca The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties. For other inquiries related to this communication, please contact Health Canada at: Marketed Health Products Directorate (MHPD) E-mail: MHPD_DPSC@hc-sc.gc.ca Tel: (613) 954-6522 Fax: (613) 952-7738 SOURCE: Wyeth

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.